TMB‑365
Monotherapy for HIV‑1
Phase 2Active
Key Facts
About TaiMed Biologics
TaiMed Biologics combines CD4‑targeted biologics with CDMO services to address HIV and autoimmune markets.
View full company profileMonotherapy for HIV‑1
TaiMed Biologics combines CD4‑targeted biologics with CDMO services to address HIV and autoimmune markets.
View full company profile